Strategic Advisors LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,748 shares of the medical research company’s stock after acquiring an additional 721 shares during the quarter. Strategic Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,471,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Hudson Valley Investment Advisors Inc. ADV grew its holdings in Thermo Fisher Scientific by 1.7% in the 4th quarter. Hudson Valley Investment Advisors Inc. ADV now owns 43,354 shares of the medical research company’s stock valued at $8,232,000 after buying an additional 716 shares in the last quarter. Legacy Private Trust Co. grew its holdings in Thermo Fisher Scientific by 60.1% in the 4th quarter. Legacy Private Trust Co. now owns 13,413 shares of the medical research company’s stock valued at $2,547,000 after buying an additional 5,034 shares in the last quarter. Oliver Luxxe Assets LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $3,335,000. Atria Investments LLC grew its holdings in Thermo Fisher Scientific by 4.6% in the 4th quarter. Atria Investments LLC now owns 8,254 shares of the medical research company’s stock valued at $1,567,000 after buying an additional 364 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Thermo Fisher Scientific by 0.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 158,812 shares of the medical research company’s stock valued at $30,155,000 after buying an additional 800 shares in the last quarter. 86.25% of the stock is currently owned by institutional investors and hedge funds.
Thermo Fisher Scientific Inc. (NYSE TMO) traded down $2.16 during trading hours on Tuesday, hitting $208.01. The stock had a trading volume of 2,235,881 shares, compared to its average volume of 1,542,556. The company has a market cap of $83,160.00, a P/E ratio of 35.32, a price-to-earnings-growth ratio of 1.71 and a beta of 1.06. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. Thermo Fisher Scientific Inc. has a 1 year low of $140.00 and a 1 year high of $211.54.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The company’s revenue was up 13.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.03 EPS. analysts expect that Thermo Fisher Scientific Inc. will post 9.36 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, January 15th. Investors of record on Friday, December 15th were given a dividend of $0.15 per share. The ex-dividend date was Thursday, December 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.
In related news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the completion of the sale, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The sale was disclosed in a filing with the SEC, which is available through this link. 0.49% of the stock is owned by corporate insiders.
A number of research analysts have commented on the company. Zacks Investment Research lowered Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. BTIG Research assumed coverage on Thermo Fisher Scientific in a report on Friday, January 5th. They issued a “buy” rating and a $230.00 price objective on the stock. Evercore ISI started coverage on Thermo Fisher Scientific in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 price objective on the stock. Leerink Swann reiterated an “outperform” rating and set a $200.00 target price (down from $216.00) on shares of Thermo Fisher Scientific in a research report on Monday, December 4th. Finally, Deutsche Bank set a $226.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $212.21.
ILLEGAL ACTIVITY NOTICE: “Thermo Fisher Scientific Inc. (TMO) Position Lifted by Strategic Advisors LLC” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/16/thermo-fisher-scientific-inc-tmo-position-lifted-by-strategic-advisors-llc.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.